FDA Grants Breakthrough Device Status to Urine-Based Alzheimer's Test

What Happened

TOBY, Inc., a biotechnology company focused on non-invasive disease detection, announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its urine-based diagnostic test for Alzheimer's disease. The designation, granted by the FDA, is intended to accelerate the development, assessment, and review of medical devices that provide more effective diagnosis of life-threatening or irreversibly debilitating conditions.

Background

Alzheimer's disease affects tens of millions of people worldwide and is currently diagnosed through a combination of cognitive assessments, brain imaging, and, increasingly, blood-based or cerebrospinal fluid biomarker tests. Cerebrospinal fluid testing requires a lumbar puncture, an invasive procedure, while PET imaging for amyloid plaques remains expensive and not widely accessible. Blood-based tests have advanced significantly in recent years but still require venipuncture and laboratory processing.

TOBY, Inc. is developing diagnostics that rely on urine samples, which the company positions as a lower-barrier alternative. The company describes itself as focused on non-invasive disease detection technologies, though specific details about the biomarkers targeted by its Alzheimer's test, and the clinical data underpinning the FDA designation request, were not disclosed in the announcement.

What the FDA Designation Means

Breakthrough Device Designation is a formal FDA program that provides eligible device developers with more frequent and interactive communication with FDA reviewers during the development and review process. It does not constitute FDA approval or clearance of the device, and it does not guarantee a pathway to market. The designation applies to devices intended to diagnose, treat, or mitigate life-threatening or irreversibly debilitating diseases where existing alternatives are inadequate.

Receiving the designation means TOBY's urine-based Alzheimer's test has been assessed by the FDA as potentially offering advantages over currently available diagnostic options. The FDA can still require additional clinical data before the device proceeds to full review.

The Diagnostic Landscape

The Alzheimer's diagnostics market has seen accelerating activity following the approval of disease-modifying therapies, including lecanemab and donanemab, which require confirmed amyloid pathology before treatment can begin. That requirement has increased clinical demand for accessible, accurate diagnostic tools. Several companies are competing in the biomarker diagnostics space, including Fujirebio and Roche, which have received FDA clearance for blood-based amyloid and phosphorylated tau tests.

A urine-based test, if validated and approved, would represent a distinct approach. Urine collection requires no medical procedure and can be performed outside clinical settings, which could lower barriers to screening in primary care or community health contexts. However, detecting Alzheimer's-related biomarkers in urine has historically presented scientific challenges due to the lower concentration of central nervous system proteins in urine compared to blood or cerebrospinal fluid.

TOBY did not disclose in the announcement which specific biomarkers its test measures, the sensitivity and specificity data from any completed studies, or the current stage of its clinical trial program.

Company Position

TOBY, Inc. describes itself as a biotechnology company but has a limited public profile compared to larger diagnostics firms. The FDA Breakthrough Device Designation represents its most prominent regulatory milestone to date based on available public information. No partnership or commercialisation agreements were announced alongside the designation.

The company did not provide spokesperson quotes in the wire report beyond the formal announcement of the designation.

What Happens Next

With Breakthrough Device Designation in place, TOBY, Inc. will be eligible for priority interaction with FDA staff as it advances its clinical development program, with the timeline for any formal FDA submission dependent on the completion of required clinical validation studies.